Log in to your Inderes Free account to see all free content on this page.
CombiGene
2.58
SEK
-0.77 %
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-0.77%
+24.04%
-6.52%
-20.37%
-4.09%
+7.05%
-77.91%
-88.32%
-97.31%
combigene.com
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Revenue
5.54M
EBIT %
-696.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
COMBI
Daily low / high price
2.42 / 2.72
SEK
Market cap
51.09M SEK
Turnover
25.01K SEK
Volume
9.9K
Financial calendar
Extraordinary general meeting
10.12.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Orpahazyme AS | 10.0 % | 10.0 % |
Jan Ivar Nordqvist | 9.5 % | 9.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Shareholders’ proposal for election of Board of Directors
Interim report January – September 2024 for CombiGene AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio